- Policy
- AD drug Dupixent’s fails 1st negotiations for RSA renewal
- by Lee, Tak-Sun Oct 12, 2023 05:37am
- The first round of negotiations to renew the risk-sharing agreement (RSA) contract for the severe atopic dermatitis treatment ‘Dupixent (dupilumab, Sanofi)’ has fallen through. The company and the National Health Insurance Service plan to discuss Dupixent’s RSA renewal through additional negotiations. According to the industry on t
- Policy
- 75% of patients who administered Kymriah is not effective
- by Lee, Jeong-Hwan Oct 11, 2023 05:37am
- More than 75% of patients who received the ultra-high-priced drug Kymriah, which costs 360 million won in one dose, did not have an improvement effect. On the 6th, Kim Young-joo, a member of the National Assembly Health and Welfare Committee (the Democratic Party, Yeongdeungpo Gap) received data from the Health Insurance Review and Assess
- Policy
- ‘Little progress for NIP support of 9-valent HPV vaccines'
- by Lee, Jeong-Hwan Oct 11, 2023 05:36am
- The number of patients receiving treatment for head and neck cancer and oropharyngeal cancer, both of which are caused by HPV (human papillomavirus), is on the rise. In just a decade, from 2013 to last year, the number of head and neck cancer patients increased by 41.6%, and the number of oropharyngeal cancer patients increased by 56%. In
- Policy
- Eisai’s Jyseleca completes negotiations with NHIS for reimb
- by Lee, Tak-Sun Oct 11, 2023 05:36am
- Eisai Korea has completed negotiations with the National Health Insurance Service for its JAK inhibitor ‘Jyseleca Tab (filgotinib).’ As a result, Jyseleca is now on the verge of being listed for reimbursement in Korea. This drug is the 5th JAK inhibitor introduced to Korea. It has a mechanism of action that selectively inhibits JAK1, t
- Policy
- Hyaluronic acid eye drops, start to revise the standard
- by Lee, Tak-Sun Oct 11, 2023 05:36am
- The HIRA has started to revise the standards to limit the use of Hyaluronic acid sodium eye drops. It is known that the revision of standards will be completed as early as the end of the year, and will be implemented from next year. According to an industry example on the 10th, the HIRA has entered a review of the revision of the standards f
- Policy
- Tepmetko attempts reimb again in KOR
- by Lee, Tak-Sun Oct 10, 2023 05:27am
- Merck is reattempting reimbursement listing of its MET-targeted anticancer therapy ‘Tepmetko (tepotinib)’ in Korea. The drug was unable to pass the Health Insurance Review and Assessment Service’s Cancer Disease Deliberation Committee review in February. The company voluntarily withdrew its reimbursement process at the time. The c
- Policy
- Will Leclaza also begin drug price negotiations soon?
- by Lee, Tak-Sun Oct 10, 2023 05:26am
- The expansion of reimbursement for Leclaza, a third-generation EGFR TKI non-small cell lung cancer treatment developed by Yuhan Corporation, as a first-line treatment will be discussed at the HIRA Pharmaceutical Reimbursement Evaluation Committee on the 12th. If the Pharmaceutical Reimbursement Evaluation Committee recognizes the adequacy of
- Policy
- Pfizer applies for reimb of its COVID-19 Tx Paxlovid
- by Lee, Tak-Sun Oct 6, 2023 05:36am
- Pfizer applied for the reimbursement of its COVID-19 treatment 'Paxlovid' in Korea. With the government planning to end the current free support system for COVID-19 treatments in the 1H next year, the company has begun the process of applying for reimbursement accordingly. According to the industry on the 5th, Pfizer Korea recently s
- Policy
- Reducing criminal liability for essential healthcare
- by Lee, Jeong-Hwan Oct 6, 2023 05:36am
- The ruling party proposed legislation to reduce criminal liability for doctors embroiled in medical malpractice suits while providing essential health services, and for the state and local governments to support and foster essential healthcare personnel. The legislation is in line with the Yoon Suk Yeol administration's policies to streng
- Policy
- Health plans expected to be implemented after NA audit
- by Lee, Jeong-Hwan Oct 5, 2023 05:27am
- The preferential drug price policy plan that reflects the value of new drugs and the 2nd comprehensive national health insurance plan, which the pharmaceutical and bio-industry are closely eyeing, is expected to be unveiled after the National Assembly audit this year. The amendment to the Instructions for the Biohealth Innovation Committe
